|
Post by afrezzamiracle on Jan 20, 2017 15:01:31 GMT -5
Yes, management was dealt a poor hand, and yes we are backed into a corner. The only thing that matters now is sales revenue, and regardless of managements efforts by any measure scripts and resulting sales revenue is a sad pathetic unimaginably low joke.
I hope Mike C's previous experience is enough to guide us toward the promised land before our very limited cash dwindles away for the last time. I've been in this stock for many years so bash if you want, but we are in dire straits. I'm wondering for the first time if the end is near after believing for so many years. AFREZZA flat out works, so this makes me sick that we are completely inept in reaching ANY sales traction what so ever. Pathetic!
|
|
|
Post by bradleysbest on Jan 20, 2017 15:06:26 GMT -5
The cold hard truth is that Afrezza works & works good! Hopefully MNKD has the funding to see Afrezza succeed.
|
|
|
Post by afrezzamiracle on Jan 20, 2017 15:16:14 GMT -5
In the right hands our ceiling is the most valuable, best selling drug in history. But our floor? I'm sad to report, that is where we have been living for many months. If we could only peer into the crystal ball to see the end game... How does this story end?!
|
|
|
Post by mango on Jan 20, 2017 15:26:03 GMT -5
Perhaps you are not aware that MannKind is currently transitioning from contract sales reps to hiring their own. I think Matt maybe said at the JP Morgan Healthcare Conference that the contract sales reps would be done by the end of January, in which, a person's desire to join MannKind full-time is their choice, which completely changes things. Matt said that script count would remain poor until the transformation is completed. Then, the new employees will have to be educated and trained before visiting providers. Relax, they have not even begun to tap into where all the patients are—primary care clinics. In the meantime, MannKind is working on completing the pediatric clinic trials, and also trials for improved dose titration. Label change is in progress. The Epi program is still a green light, and Matt also indicated that they will be targeting select audiences with TV commercials, and even better, are working a reality TV deal that will heavily show Afrezza.
I cannot reason with your thinking that everything should blast off overnight. Transforming a company on a shoestring budget and only one product is no easy accomplishment, yet, MannKind has succeeded in doing so. Script count will not increase in any meaningful way for a little while. You were told this by the CEO. There was even charts illustrating this.. It is misinformation to claim management has failed. I see MannKind building the necessary foundation for long-term success.
|
|
|
Post by sweedee79 on Jan 20, 2017 15:31:51 GMT -5
Yes, management was dealt a poor hand, and yes we are backed into a corner. The only thing that matters now is sales revenue, and regardless of managements efforts by any measure scripts and resulting sales revenue is a sad pathetic unimaginably low joke. I hope Mike C's previous experience is enough to guide us toward the promised land before our very limited cash dwindles away for the last time. I've been in this stock for many years so bash if you want, but we are in dire straits. I'm wondering for the first time if the end is near after believing for so many years. AFREZZA flat out works, so this makes me sick that we are completely inept in reaching ANY sales traction what so ever. Pathetic! I wish we had a DISLIKE button sometimes ......
yes things are tense.... we don't have a lot of money..... however, management has done quite well in the past few months..... we may go broke... YES... but we all have known that since SNY handed Afrezza back to us..... what did you expect given the circumstances??? .... We may succeed.... we may go broke....... just the way it is.... what I see is that management is still trying.... so it isn't over yet.... I don't plan to sell.... not yet... I haven't lost hope... nor am I hanging my hat on the weekly sales reports considering that we have only been able to afford a minimal sales team, that which is being improved... also, insurance is still a problem..... which in fact is improving.... I believe that when sales do start to pick up substantially.... it will be a fast move upward... so even if sales aren't that great right now.... doesn't mean that tells the whole story... and no, I don't have my head in a sand bucket.... I am as realistic as you are... just don't see things the same way....
|
|
|
Post by kc on Jan 20, 2017 16:00:00 GMT -5
The cold hard truth is that Afrezza works & works good! Hopefully MNKD has the funding to see Afrezza succeed. Or make a deal to sell to the right new Pharma who will help Afrezza achieve its potential. Bankruptcy as I have stated for over 12 months is not good for common shareholders or the Mann Family. I hope that the board and Management know and sell the company to avoid that from happening.
|
|
|
Post by afrezzamiracle on Jan 20, 2017 16:07:00 GMT -5
I sincerely appreciate that progress is being made on many fronts, and there seems to be a number of positive things going on, but sadly only green cash pays the bills. It's all 100% about the money. The fact is that our sales are so bad that calling them horrible would be generous. We can cite positives until we are blue in the face, meanwhile the company goes bankrupt because we are incompetent at doing the one and only one thing that really matters--selling a large quantity of AFREZZA. If we don't figure that one factor out soon, all the other ones will soon be completely irrelevant.
|
|
Deleted
Deleted Member
Posts: 0
|
Post by Deleted on Jan 20, 2017 16:10:13 GMT -5
In the meantime, MannKind is working on completing the pediatric clinic trials The have been working on the protocol. Lets wait for the protocol to complete. - hope the protocol is so complicated that its taking so long. then register the trials with fda. Recruit Start collecting data and ... and... and.... Successful management usually will have timelines defined and will work for them At this point in time, though they cannot disclose them to investors, hope they have them defined. Ever wonder why the protocol is taking so much time? I dont.
|
|
|
Post by zuegirdor on Jan 20, 2017 16:53:52 GMT -5
Don't want to sound like a Pollanna. Certainly there are risks in this venture. We are also beset by the economic and market changes of the last few decades. It takes so much funding to overcome market and medical inertia that it is a wonder anything ever gets done.
How many here are aware that there is a treatment for toxic mushroom poisoning that has been a folk remedy in Europe (where wild mushroom collecting and eating is as common as picnicing)for centuries. It is called Milk Thistle extract and the mechanism by which it works to save lives was revealed by research within the last 5 years. I happen to be a collector myself and know through the grapevine that you have to carry a card in your wallet insisting on compassionate treatment with Milk Thistle because the standard of treatment, basically comfort the victim and find a new liver if possible, still has not caught up with the research.
Same with Afrezza. We just better hope there is enough commitment (and funding?) by management to weather the storm of ignorance and venality, that is upon us from all directions, until some bright angel of our collective better nature knocks some sense into us. The potential for this drug is huge (at least until there is a true cure).
We have been trialing Afrezza for my son and it is amazing....and expensive. but nothing else can stomp a high blood sugar or a meal spike like Afrezza. (Never done intramuscular but cannot believe it would be as fast as Afrezza)
Most recently I have changed my mind about the practicality of using Afrezza with the new FDA approved version of an Artificial Pancreas (AP). As some may be aware this version still requires the user to program boluses for meals. Some say this means its not a true AP but I think such an hands off AP is a pipe dream as long as it is using subcutaneous insulin or even apidra and analogues.
No doubt the JDRF funded creators of this AP are well aware of the limitations of Subcu Insulin. That is why, in public announcements of its development, they early on attached the ultimate application of the AP to the use of Afrezza.
Now I understand how the two products used in tandem will contribute to the ultimate success of both, Bear with me as I describe how this winning combination may be designed to work: The patient inserts one of these very small and tubeless AP (basically combining an omnipod pump with CGM within a single compact device). AP can respond safely and effectively to small and slow changes in blood glucose due to programming that administers insulin incrementally according to slope and duration of blood glucose changes. This should be good enough (as determined by their research, presumably)except when sugars rise fast immediately after a meal. That is where Afrezza comes in. But unlike the way my son must use Afrezza, with the AP Afrezza only needs to be taken once-at the begining of the meal. This one time dose could be an 8 or a 4 or a 12 unit cartridge depending on the meal. its only purpose is to provide first phase insulin that the subcutaneous insulin can not provide.
So instead of needing 6 to 10 cartridges a day of Afrezza, diabetics on the AP would need only three- or four if they want a snack or pizza(?). There! We have just eliminated the cost barrier for Afrezza by a half to a third or more. Whats more the patient does not even have to think about how to time the follow up dose (which my son often forgets entirely). The AP Afrezza combo would eliminate the difficult "titration adjustment period" Afrezza users experience since all users would use the single first phase dose method for meals. This would be almost carefree control and it would be very tight control as well. I think sub 6.0 A1Cs should be possible if not common on this combination. Even more important, it would ensure most diabetics enjoy a complication free normal lifespan.
Of course APs are not for everyone, so some may still prefer other combinations and delivery methods of all insulins. Choice is paramount. But were choice the only factor, we would already have thousands using the AP Afrezza combo. I am certain of it.
|
|
|
Post by afrezzamiracle on Jan 20, 2017 17:05:54 GMT -5
Sounds like we need to lower the price so patient choice, and AFREZZA's superiority can rule the day. What we have done to date is obviously NOT working. We have an amazing production facility in Danbury that can produce AFREZZA for millions of diabetics, yet we are essentially selling ZERO product.
|
|
|
Post by zuegirdor on Jan 20, 2017 17:07:03 GMT -5
I wonder what kind of buyer would be most invested, er...interested, in Afrezza if it were to be put up for sale.....?
|
|
|
Post by gamblerjag on Jan 20, 2017 17:27:30 GMT -5
I'm guessing a smart BP with the intelligence to see that saving lives and making mula befefits everyone.
|
|
|
Post by wgreystone on Jan 20, 2017 17:52:28 GMT -5
Perhaps you are not aware that MannKind is currently transitioning from contract sales reps to hiring their own. I think Matt maybe said at the JP Morgan Healthcare Conference that the contract sales reps would be done by the end of January, in which, a person's desire to join MannKind full-time is their choice, which completely changes things. Matt said that script count would remain poor until the transformation is completed. Then, the new employees will have to be educated and trained before visiting providers. Relax, they have not even begun to tap into where all the patients are—primary care clinics. In the meantime, MannKind is working on completing the pediatric clinic trials, and also trials for improved dose titration. Label change is in progress. The Epi program is still a green light, and Matt also indicated that they will be targeting select audiences with TV commercials, and even better, are working a reality TV deal that will heavily show Afrezza. I cannot reason with your thinking that everything should blast off overnight. Transforming a company on a shoestring budget and only one product is no easy accomplishment, yet, MannKind has succeeded in doing so. Script count will not increase in any meaningful way for a little while. You were told this by the CEO. There was even charts illustrating this.. It is misinformation to claim management has failed. I see MannKind building the necessary foundation for long-term success. IMHO, hiring sales reps alone will not solve the puzzle. Management didn't tell us why it's so hard to persuade doctors to prescribe Afrezza. They used to blame spirometers but that problem seems resolved now. My guess is insurance coverage. We need preferred coverage without any PA. Otherwise doctors will be reluctant to spend time on dealing with insurance unless patients really push hard.
|
|
|
Post by bradleysbest on Jan 20, 2017 18:15:55 GMT -5
Bingo!
|
|
|
Post by sayhey24 on Jan 20, 2017 18:45:49 GMT -5
Perhaps you are not aware that MannKind is currently transitioning from contract sales reps to hiring their own. I think Matt maybe said at the JP Morgan Healthcare Conference that the contract sales reps would be done by the end of January, in which, a person's desire to join MannKind full-time is their choice, which completely changes things. Matt said that script count would remain poor until the transformation is completed. Then, the new employees will have to be educated and trained before visiting providers. Relax, they have not even begun to tap into where all the patients are—primary care clinics. In the meantime, MannKind is working on completing the pediatric clinic trials, and also trials for improved dose titration. Label change is in progress. The Epi program is still a green light, and Matt also indicated that they will be targeting select audiences with TV commercials, and even better, are working a reality TV deal that will heavily show Afrezza. I cannot reason with your thinking that everything should blast off overnight. Transforming a company on a shoestring budget and only one product is no easy accomplishment, yet, MannKind has succeeded in doing so. Script count will not increase in any meaningful way for a little while. You were told this by the CEO. There was even charts illustrating this.. It is misinformation to claim management has failed. I see MannKind building the necessary foundation for long-term success. IMHO, hiring sales reps alone will not solve the puzzle. Management didn't tell us why it's so hard to persuade doctors to prescribe Afrezza. They used to blame spirometers but that problem seems resolved now. My guess is insurance coverage. We need preferred coverage without any PA. Otherwise doctors will be reluctant to spend time on dealing with insurance unless patients really push hard. My first question would be the same one Mike C. asked when he first came on board last year- where are the refills, whats the issue? I thought Mike told us last year he was going to fix this. As part of the answer I would also like to know why Vdex failed. My second question would be what are these sales reps selling and to whom? If they are sending them out to sell a "faster than RAA insulin which is inhaled" I can tell you it did not work for Sanofi and it did not work for the contractors. You know what they say about doing the same thing over and over again and getting the same result. I would suggest they first figure out what their product is and then package it accordingly and price it accordingly. Then they better figure out how they are going to market it and have some real advertising both paid and earned. As part of that they have the clamp studies but they may need more with a well defined patient protocol. Then they can send out the sales guys. Can they get all done in the next 6 months, lets hope because that's about how long it will take to get in the endo's front door.
|
|